CAR-T therapy has revolutionized cancer treatment, offering a personalized approach that uses genetically modified T cells to target and destroy cancer cells. However, this breakthrough treatment comes at a steep price. In the U.S., CAR-T therapies are priced between $300,000 and $600,000, and when factoring in the costs of treating adverse reactions and hospital stays, the total expenditure can exceed $1,000,000. The high cost makes it inaccessible for many patients and poses a challenge for healthcare systems worldwide.
To address this issue, experts and industry leaders have proposed several strategies to reduce the cost of CAR-T therapy while maintaining its efficacy and accessibility.
Producing the Therapy in Countries with Lower Manufacturing Costs
One of the most effective ways to curb CAR-T costs is by manufacturing the therapy in countries where production is more affordable. For instance, ImmunoACT, a small biotech company in Mumbai, India, has developed NexCAR19, a CAR-T therapy that costs between $20,000 and $40,000—roughly a tenth of what similar therapies are priced at in the U.S.
The cost savings stem from lower labor expenses and the company’s ability to manufacture its own viral vectors, a major cost driver in the CAR-T production process.
Implementing Point-of-Care Manufacturing
Another promising solution is the point-of-care manufacturing model, which allows hospitals and research institutions to produce CAR-T therapies on-site. By eliminating the need for extensive supply chains and middlemen, this approach significantly cuts costs and reduces wait times for patients.
For example, a hospital in Barcelona, Spain, manufactures its own CAR-T therapy and provides it to patients for $97,000, far less than the cost of name-brand therapies.
Similarly, in Brazil, the Oswaldo Cruz Foundation, Latin America’s largest biomedical research institute, has partnered with U.S.-based nonprofit Caring Cross to establish local CAR-T production capabilities. Caring Cross has developed a point-of-care manufacturing model that can generate CAR-T therapies at a cost of $20,000 in materials and $10,000 in labor and facility expenses.
Another example of progress in this area is the benchtop CliniMACS Prodigy instrument from Miltenyi Biotec, which can produce autologous CAR-T cells just in eight days.
Similarly, in 2022, a research team in the Perelman School of Medicine at the University of Pennsylvania developed a process to generate functional CAR-T cells in 24 hours.
Developing Off-the-Shelf (Allogeneic) CAR-T Therapies
Traditional CAR-T therapies are autologous, meaning they are custom-made for each patient using their own T cells. This bespoke approach contributes to the high costs, as each batch must be uniquely engineered.
However, many companies are now developing allogeneic, or off-the-shelf, CAR-T therapies, which involve engineering T cells from healthy donors. These ready-made treatments have the potential to be produced at scale, significantly reducing costs while maintaining effectiveness.
Engineering CAR-T Cells Inside the Body (In Vivo CAR-T)
Conventional CAR-T therapy requires extracting a patient’s T cells, modifying them in a lab, and then reinfusing them—a process that is both complex and expensive. A new approach, in vivo CAR-T, seeks to eliminate these costly steps by engineering CAR-T cells directly within the patient’s body.
This method would remove the need for extensive cell manipulation and specialized treatment centers, making CAR-T therapy more accessible and affordable. Companies like Capstan Therapeutics are leading the development of in vivo CAR-T therapies, which could revolutionize the treatment landscape.
Currently, CAR-T therapy is primarily used for certain blood cancers, but researchers are exploring its potential for treating other conditions, including solid tumors, heart disease, aging-related diseases, and HIV infections.
As CAR-T therapies expand to a broader range of medical indications, economies of scale may help drive down costs, making the treatment more widely available.
Conclusions
CAR-T therapy has the potential to transform medicine, but its high cost remains a significant barrier. By adopting strategies such as producing CAR-T therapies in cost-effective regions, implementing point-of-care manufacturing, developing off-the-shelf options, engineering CAR-T cells in vivo, and expanding its indications, the industry can make these life-saving treatments more affordable.
As technology advances and manufacturing processes improve, the hope is that CAR-T therapy will become accessible to all patients who need it, regardless of financial constraints. By removing this bottleneck to adoption, CAR-T cell therapies could increase from 13 globally approved therapies (seven within the U.S.) to dozens worldwide.
